Le masitinib reçoit la désignation de médicament orphelin pour le traitement de la sclérose latérale amyotrophique en Suisse
27 déc. 2022 13h04 HE
|
AB Science
COMMUNIQUE DE PRESSE LE MASITINIB REÇOIT LA DÉSIGNATION DE MÉDICAMENT ORPHELIN POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) EN SUISSE Paris, 26 décembre 2022, 19h AB Science SA...
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
21 déc. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion...
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
05 déc. 2022 07h30 HE
|
Athira Pharma, Inc.
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS Data adds to the growing body of evidence...
Major investment in top talent in ALS research
24 nov. 2022 09h00 HE
|
ALS Society of Canada
Toronto, ON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are powering innovative discoveries and treatments for amyotrophic lateral sclerosis (ALS)...
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
14 nov. 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S....
Lifestyle Healing Institute Shares an ALS Success Story
07 nov. 2022 08h00 HE
|
Lifestyle Healing Institute
NAPLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- When he started having trouble moving the fingers of his left hand, Tod saw a neurologist for tests. He was stunned by the diagnosis: amyotrophic...
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
03 nov. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter...
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
24 oct. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society...
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
17 oct. 2022 07h30 HE
|
Biogen Inc.
The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the...
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
03 oct. 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A...